US · Healthcare · Biotechnology
EPS came in at 1.30 against a street estimate of 1.18 — a beat of 10.2%.
Analysts rate Royalty Pharma Plc a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $59.89.
| Fund | Stake |
|---|---|
| Morgan Stanley - Brokerage Accounts | 9.83% |
| Capital Research & Mgmt Co - Division 3 | 7.90% |
| BlackRock Inc | 5.84% |
| FMR Inc | 5.67% |
| Baillie Gifford & Co Limited. | 3.64% |
| State Street Corp | 2.48% |
| Swedbank AB | 2.42% |
| Capital World Investors | 1.81% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-04 |
| Material agreement · Q2 2026 | 2026-05-28 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Reg FD disclosure · Q2 2026 | 2026-04-13 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Annual report FY2025 | 2026-02-11 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.23 / share ex-date Aug 14, 2026 · pay Sep 10, 2026 | 2026-08-14 |
| Dividend | $0.23 / share ex-date May 15, 2026 · pay Jun 10, 2026 | 2026-05-15 |
| Dividend | $0.23 / share ex-date Feb 20, 2026 · pay Mar 10, 2026 | 2026-02-20 |
| Dividend | $0.22 / share ex-date Nov 14, 2025 · pay Dec 10, 2025 | 2025-11-14 |
| Dividend | $0.22 / share ex-date Aug 15, 2025 · pay Sep 10, 2025 | 2025-08-15 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Royalty Pharma Plc — free to start.
Google PlayApp StoreData updated 2026-08-05.